Residential School on Medicinal Chemistry and Biology in Drug Discovery

 

Drew University’s Residential School on Medicinal Chemistry and Biology in Drug Discovery (ResMed)

IMPORTANT INFORMATION

The ResMed staff and Drew University are continuing to monitor developments related to the coronavirus disease (COVID-19) outbreak and potential impact on the ResMed 2020 course scheduled for June 7-12, 2020. Any changes to the status of ResMed 2020 will be communicated immediately to all registered attendees and posted on the course website.
For the most up-to-date information on how Drew is responding to the virus, please refer to Drew’s Coronavirus Disease 2019 emergency page, and for national information, please refer to the U.S. Centers for Disease Control and Prevention website.

Keynote 2020

Michael J. Sofia, Ph.D. is Co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc. a company focused on the discovery and development of therapies to cure hepatitis B. Previously Mike was Sr. Vice President of Chemistry at Pharmasset, Inc. Mike has also held research and research management positions at Gilead Sciences, Bristol-Myers Squibb, Transcell Technologies and Eli Lilly and Company…

Drew University’s Residential School on Medicinal Chemistry and Biology in Drug Discovery (ResMed) course will be held June 7-12, 2020 at the Hyatt Regency-Morristown.

ResMed is a graduate level course designed for chemists and biologists  interested in broadening their understanding of the fundamental principles of drug discovery research and pre-clinical development. Scientists from related disciplines would also gain a clearer appreciation for the processes and methods important to drug discovery through clinical development.

Course attendees staying at the hotel will enjoy beautifully appointed, single-occupancy rooms and a breakfast buffet.

Case History Spotlight

ResMed provides case histories for drugs that have successfully made it from the “bench to the bedside”: BELSOMRA® (suvorexant, insomnia), Erivedge® (vismodegib, basal cell carcinoma), PROMACTA® (eltrombopag, thrombocytopenia), and Trikafta™ (elexacaftor/ivacaftor/tezacaftor), a new combination therapy for cystic fibrosis recently approved by the FDA.